MX2023001319A - Polipeptidos condicionalmente activos. - Google Patents

Polipeptidos condicionalmente activos.

Info

Publication number
MX2023001319A
MX2023001319A MX2023001319A MX2023001319A MX2023001319A MX 2023001319 A MX2023001319 A MX 2023001319A MX 2023001319 A MX2023001319 A MX 2023001319A MX 2023001319 A MX2023001319 A MX 2023001319A MX 2023001319 A MX2023001319 A MX 2023001319A
Authority
MX
Mexico
Prior art keywords
species
conditionally active
active polypeptides
polypeptide
pka
Prior art date
Application number
MX2023001319A
Other languages
English (en)
Inventor
Gerhard Frey
Hwai Wen Chang
Jay M Short
Original Assignee
Bioatla Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2016/019242 external-priority patent/WO2016138071A1/en
Application filed by Bioatla Llc filed Critical Bioatla Llc
Publication of MX2023001319A publication Critical patent/MX2023001319A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Wood Science & Technology (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)

Abstract

Un polipéptido no natural o polipéptido aislado que tiene una relación de al menos 1.3 de una actividad en un ensayo a un primer pH en presencia de al menos una especie que tiene un peso molecular de menos de 900 a.m.u. y un pKa de hasta 4 unidades de diferencias con respecto a dicho primer pH, a una actividad en un ensayo a un segundo pH en presencia de la misma al menos una especie. La especie tiene un pKa entre dicho primer pH y dicho segundo pH y puede ser una molécula pequeña. También se divulgan formulaciones farmacéuticas que incluyen el polipéptido y sus usos. También se divulgan métodos para producir polipéptidos condicionalmente activos.
MX2023001319A 2015-11-02 2018-04-24 Polipeptidos condicionalmente activos. MX2023001319A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562249907P 2015-11-02 2015-11-02
PCT/US2016/019242 WO2016138071A1 (en) 2015-02-24 2016-02-24 Conditionally active biological proteins
PCT/US2016/049715 WO2017078839A1 (en) 2015-11-02 2016-08-31 Conditionally active polypeptides

Publications (1)

Publication Number Publication Date
MX2023001319A true MX2023001319A (es) 2023-02-22

Family

ID=58662272

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018005063A MX2018005063A (es) 2015-11-02 2016-08-31 Polipéptidos condicionalmente activos.
MX2023001319A MX2023001319A (es) 2015-11-02 2018-04-24 Polipeptidos condicionalmente activos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2018005063A MX2018005063A (es) 2015-11-02 2016-08-31 Polipéptidos condicionalmente activos.

Country Status (11)

Country Link
US (2) US11472876B2 (es)
EP (1) EP3371349A1 (es)
JP (3) JP7064769B2 (es)
KR (1) KR20180064534A (es)
CN (2) CN108473555B (es)
AU (2) AU2016350613B2 (es)
CA (1) CA3003399A1 (es)
HK (1) HK1253684A1 (es)
MX (2) MX2018005063A (es)
RU (1) RU2735023C9 (es)
WO (1) WO2017078839A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2913205T3 (es) * 2014-05-13 2022-06-01 Bioatla Inc Proteínas biológicas activas condicionalmente
CA3003399A1 (en) * 2015-11-02 2017-05-11 Bioatla, Llc Conditionally active polypeptides
EP3403098B1 (en) * 2016-01-12 2021-09-22 BioAtla, Inc. Diagnostics using conditionally active antibodies
US10697972B2 (en) 2016-01-12 2020-06-30 Bioatla, Llc Diagnostics using conditionally active antibodies
EP3443001A4 (en) 2016-04-11 2020-04-29 Obsidian Therapeutics, Inc. REGULATED BIOCIRCUIT SYSTEMS
AU2017320874B2 (en) * 2016-08-31 2024-03-07 Bioatla, Llc Conditionally active polypeptides and methods of generating them
KR20230132603A (ko) 2017-01-11 2023-09-15 브리스톨-마이어스 스큅 컴퍼니 Psgl-1 길항제 및 그의 용도
JP7211961B2 (ja) 2017-03-14 2023-01-24 ファイヴ プライム セラピューティクス インク 酸性ｐＨでＶＩＳＴＡに結合する抗体
AU2019286396A1 (en) * 2018-06-14 2020-12-17 Bioatla, Inc. Multi-specific antibody constructs
JP2021534194A (ja) * 2018-08-21 2021-12-09 バイオアトラ インコーポレイテッド ｐＨ選択性を有する条件的活性型タンパク質

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
EP0623679B1 (en) 1987-05-21 2003-06-25 Micromet AG Targeted multifunctional proteins
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
KR900005995A (ko) 1988-10-31 1990-05-07 우메모또 요시마사 변형 인터류킨-2 및 그의 제조방법
EP0394827A1 (en) 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Chimaeric CD4-immunoglobulin polypeptides
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
WO1991006570A1 (en) 1989-10-25 1991-05-16 The University Of Melbourne HYBRID Fc RECEPTOR MOLECULES
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
DE69123241T2 (de) 1990-12-14 1997-04-17 Cell Genesys Inc Chimärische ketten zur transduktion von rezeptorverbundenen signalwegen
EP0573551B1 (en) 1991-02-27 2003-05-21 Micromet AG Serine-rich peptide linkers
US5525491A (en) 1991-02-27 1996-06-11 Creative Biomolecules, Inc. Serine-rich peptide linkers
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
GB9320668D0 (en) 1993-10-07 1993-11-24 Secr Defence Liposomes containing particulare materials
GB9415379D0 (en) 1994-07-29 1994-09-21 Smithkline Beecham Plc Novel compounds
CN1117155C (zh) 1994-07-29 2003-08-06 史密丝克莱恩比彻姆有限公司 新型化合物
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
DE69627820T2 (de) 1995-01-17 2004-04-08 The Brigham And Women's Hospital Inc., Boston Rezeptorspezifischer transepithelialer transport von immunogenen
AU6330896A (en) 1995-06-07 1996-12-30 Governors Of The University Of Alberta, The A method for eliciting a th1-specific immune response
US6764835B2 (en) 1995-12-07 2004-07-20 Diversa Corporation Saturation mutageneis in directed evolution
US5723125A (en) 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
US6306393B1 (en) 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
EP1056473B8 (en) 1998-02-09 2005-07-20 Bracco International B.V. Targeted delivery of biologically active media
IL138857A0 (en) 1998-04-21 2001-10-31 Micromet Ges For Biomedizinisc Cd19xcd3 specific polypeptides and uses thereof
US20020028178A1 (en) 2000-07-12 2002-03-07 Nabil Hanna Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
US20020006404A1 (en) 1999-11-08 2002-01-17 Idec Pharmaceuticals Corporation Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
AU2001247616B2 (en) 2000-04-11 2007-06-14 Genentech, Inc. Multivalent antibodies and uses therefor
SG136804A1 (en) 2000-07-12 2007-11-29 Idec Pharma Corp Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications
MXPA03002262A (es) 2000-09-18 2003-10-15 Idec Pharma Corp Terapia de combinacion para tratamiento de enfermedades autoinmunes usando una combinacion de anticuerpos inmunorreguladores/supresores de celulas b.
US20040136908A1 (en) 2001-04-09 2004-07-15 Olson William C. Anti-cd19 immunotoxins
US20030138405A1 (en) 2001-04-17 2003-07-24 Juan Fueyo Conditionally replicative adenovirus to target the Rb and Rb-related pathways
ATE448811T1 (de) 2001-04-27 2009-12-15 Vivoxid Oy Verfahren zur verbesserung der anhaftung von weichteilgewebe und implantate, die gebrauch von diesem verfahen machen
EP1436119B2 (de) 2001-10-17 2008-08-13 Schneider GmbH + Co. KG Vorrichtung und verfahren zur komplettbearbeitung von zweiseitig optisch aktiven linsen
US20060141456A1 (en) 2002-06-12 2006-06-29 Cynthia Edwards Methods and compositions for milieu-dependent binding of a targeted agent to a target
US20040064050A1 (en) 2002-09-20 2004-04-01 Jun Liu System and method for screening tissue
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
WO2005086922A2 (en) 2004-03-10 2005-09-22 Board Of Regents, University Of Texas System Oncolytic adenovirus armed with therapeutic genes
US20050260711A1 (en) 2004-03-30 2005-11-24 Deepshikha Datta Modulating pH-sensitive binding using non-natural amino acids
BRPI0515230A (pt) * 2004-08-19 2008-07-15 Genentech Inc polipeptìdeos, anticorpos e ácidos nucléicos isolados, composições, vetor de expressão, células hospedeiras isoladas, método para a produção de um anticorpo, artigos manufaturados, métodos de tratamento e para o alìvio de disfunções, métodos de produção e de seleção de um polipeptìdeo, anticorpo de ligação cd20 humanizado, anticorpo anti-her2 isolado e usos de um anticorpo
WO2009021232A2 (en) 2007-08-09 2009-02-12 Massachusetts Institute Of Technology High-throughput, whole-animal screening system
EP3543256A1 (en) 2009-01-12 2019-09-25 Cytomx Therapeutics Inc. Modified antibody compositions, methods of making and using thereof
CN105132395A (zh) * 2009-03-09 2015-12-09 生物蛋白有限公司 Mirac蛋白
SG10201700096VA (en) 2009-07-17 2017-02-27 Bioatla Llc Simultaneous, Integrated Selection And Evolution Of Antibody/Protein Performance And Expression In Production Hosts
US20110143960A1 (en) 2009-12-10 2011-06-16 Labarbera Daniel V 3d-models for high-throughput screening drug discovery and development
US8362210B2 (en) 2010-01-19 2013-01-29 Xencor, Inc. Antibody variants with enhanced complement activity
MX349622B (es) * 2010-09-08 2017-08-07 Halozyme Inc Metodos para evaluar e identificar o evolucionar proteinas terapeuticas condicionalmente activas.
WO2013040445A1 (en) 2011-09-15 2013-03-21 Whitehead Institute For Biomedical Research Arrays for cell-based screening and uses thereof
WO2013046722A1 (ja) 2011-09-30 2013-04-04 中外製薬株式会社 イオン濃度依存性結合分子ライブラリ
AU2013229786B2 (en) 2012-03-08 2017-06-22 Halozyme, Inc. Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof
US20140206596A1 (en) * 2013-01-18 2014-07-24 University Of Southern California Design of pH-Sensitive Oligopeptide Complexes For Drug Release Under Mildly Acidic Conditions
ES2913205T3 (es) 2014-05-13 2022-06-01 Bioatla Inc Proteínas biológicas activas condicionalmente
CA3003399A1 (en) 2015-11-02 2017-05-11 Bioatla, Llc Conditionally active polypeptides

Also Published As

Publication number Publication date
JP2024020382A (ja) 2024-02-14
CN115521374A (zh) 2022-12-27
RU2018115781A3 (es) 2019-12-04
CN108473555B (zh) 2022-10-25
JP7064769B2 (ja) 2022-05-11
MX2018005063A (es) 2018-12-10
HK1253684A1 (zh) 2019-06-28
EP3371349A4 (en) 2018-09-12
JP2018534932A (ja) 2018-11-29
RU2735023C2 (ru) 2020-10-27
US20220403024A1 (en) 2022-12-22
JP2022101618A (ja) 2022-07-06
CN108473555A (zh) 2018-08-31
US20200407439A1 (en) 2020-12-31
AU2016350613A1 (en) 2018-05-24
RU2018115781A (ru) 2019-12-04
KR20180064534A (ko) 2018-06-14
AU2016350613B2 (en) 2023-10-05
JP7390748B2 (ja) 2023-12-04
EP3371349A1 (en) 2018-09-12
AU2023285915A1 (en) 2024-01-25
US11472876B2 (en) 2022-10-18
CA3003399A1 (en) 2017-05-11
WO2017078839A1 (en) 2017-05-11
RU2735023C9 (ru) 2021-06-18

Similar Documents

Publication Publication Date Title
MX2023001319A (es) Polipeptidos condicionalmente activos.
TN2017000085A1 (en) Polypeptide having a polyester degrading activity and uses thereof
AU2019201173B2 (en) Novel polypeptides
WO2018062866A3 (en) CELL-PERMEABLE (CP)-Cas9 RECOMBINANT PROTEIN AND USES THEREOF
NZ731185A (en) Bicyclic peptide ligands specific for mt1-mmp
SG10201803042PA (en) Anti-tim-3 antibodies
MX2021014704A (es) Peptidos y nanoparticulas para suministro intracelular de moleculas editoras de genoma.
WO2015179691A3 (en) Cell penetrating peptides and methods of making and using thereof
WO2015191693A3 (en) Method for gene editing
BR112017007816A2 (pt) composições farmacêuticas compreendendo variantes de peptídeos e métodos de uso das mesmas
WO2016061286A3 (en) Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
WO2018098282A3 (en) Cyclic cell penetrating peptides comprising beta-hairpin motifs and methods of making and using thereof
WO2015048498A3 (en) Carrier-free biologically-active protein nanostructures
MX2018015118A (es) Particulas y composiciones de nicotina.
WO2015198240A3 (en) Compositions and methods for long acting proteins
WO2015058173A8 (en) Stable solid units and methods of making the same
WO2015185758A3 (en) Preparation comprising factor viii and von willebrand factor peptides
PH12020500569A1 (en) Influenza virus vaccines and uses thereof
MY194351A (en) Recombinant Human-Basic Fibroblast Growth Factor (Rh-Bfgf) and Pharmaceutical Composition Comprising Rh-Bfgf
EA201591609A1 (ru) Варианты альфа-амилазы
WO2018132696A3 (en) Stomach acid-stable and mucin-binding protein-polymer conjugates
WO2016130581A8 (en) Combination cancer therapy
MY183068A (en) Pharmaceutical formulation comprising antibody
WO2018124758A3 (ko) 베타-갈락토사이드가 도입된 자가-희생 기를 포함하는 화합물
WO2015100370A3 (en) Sustained release depot formulations of therapeutic proteins, and uses thereof